コンテンツへスキップ
Merck

SML1884

Sigma-Aldrich

Mitoglitazone

≥98% (HPLC)

別名:

5-[[4-[2-(5-ethyl-2-pyridinyl)-2-oxoethoxy]phenyl]methyl]-2,4-thiazolidinedione, MSDC-0160

ログイン組織・契約価格を表示する


About This Item

実験式(ヒル表記法):
C19H18N2O4S
CAS番号:
分子量:
370.42
MDL番号:
UNSPSCコード:
12352200
NACRES:
NA.77

品質水準

アッセイ

≥98% (HPLC)

形状

powder

white to beige

溶解性

DMSO: 20 mg/mL, clear

保管温度

−20°C

SMILES記法

CCC1=CN=C(C(COC2=CC=C(CC3SC(NC3=O)=O)C=C2)=O)C=C1

InChI

1S/C19H18N2O4S/c1-2-12-5-8-15(20-10-12)16(22)11-25-14-6-3-13(4-7-14)9-17-18(23)21-19(24)26-17/h3-8,10,17H,2,9,11H2,1H3,(H,21,23,24)

InChI Key

IRNJSRAGRIZIHD-UHFFFAOYSA-N

生物化学的/生理学的作用

MSDC-0160 is an mTOT (mitochondrial target of thiazolidinediones) modulator that targets the mitochondrial pyruvate carrier (MPC), which is a key controller of cellular metabolism. MSDC-0160 is reported to enhance the cells′ ability to handle potentially harmful proteins, which leads to reduced inflammation and less nerve cell death. It has already been in clinical trials for diabetes and Alzheimer′s disease and clinical trials for Parkinson′s Disease are planned.

保管分類コード

11 - Combustible Solids

WGK

WGK 3

引火点(°F)

Not applicable

引火点(℃)

Not applicable


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Nidhi Rohatgi et al.
PloS one, 8(5), e62012-e62012 (2013-05-08)
Major bottlenecks in the expansion of human β-cell mass are limited proliferation, loss of β-cell phenotype, and increased apoptosis. In our previous studies, activation of Wnt and mTOR signaling significantly enhanced human β-cell proliferation. However, isolated human islets displayed insulin
Raj C Shah et al.
Current Alzheimer research, 11(6), 564-573 (2014-06-17)
Alzheimer's disease (AD) is associated with insulin resistance and specific regional declines in cerebral metabolism. The effects of a novel mTOT modulating insulin sensitizer (MSDC-0160) were explored in non-diabetic patients with mild AD to determine whether treatment would impact glucose
Anamitra Ghosh et al.
Science translational medicine, 8(368), 368ra174-368ra174 (2016-12-09)
Mitochondrial and autophagic dysfunction as well as neuroinflammation are involved in the pathophysiology of Parkinson's disease (PD). We hypothesized that targeting the mitochondrial pyruvate carrier (MPC), a key controller of cellular metabolism that influences mTOR (mammalian target of rapamycin) activation

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)